Trial Profile
A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors VIVUS
- 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 30 Sep 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.